Nicox: Half-year liquidity contract statement with Kepler Cheuvreux

11 Jul 2023
www.globenewswire.com
License out/in
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
Press Release Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
July 11, 2023 – release at 7:30 am CET
Sophia Antipolis, France
Under the liquidity contract entered into between Nicox and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023:
304,567 shares
€ 10,640.56
Number of executions on buy side on semester: 128
Number of executions on sell side on semester: 111
Traded volume on buy side on semester: 74,584 shares for € 62,919.32
Traded volume on sell side on semester: 58,982 shares for € 51,368.57
As a reminder:
The following resources appeared on the last half year statement on December 31, 2022 on the liquidity account:
288,965 shares
€ 22,074.60
Number of executions on buy side on semester: 274
Number of executions on sell side on semester: 195
Traded volume on buy side on semester: 155,703 shares for € 262,378.38
Traded volume on sell side on semester: 100,347 shares for € 178,155.02
The following resources appeared on the liquidity account when the activity started:
0 shares
€ 500,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
Buy Side Sell Side Number of executionsNumber of sharesTraded volume in EUR Number of executionsNumber of sharesTraded volume in EURTotal12874 58462 919.32 12874 58462 919.3202/01/2023--- 42 1702 517.2003/01/2023--- 59571 119.6904/01/202311 0001 140.00 111.1806/01/202322 0002 220.00 ---09/01/2023--- 111.1410/01/202311 0001 100.00 ---11/01/2023--- 62 0002 220.0012/01/202311 0001 100.00 135 6066 390.8413/01/202311 0001 120.00 39381 069.3216/01/202331 5001 665.00 11 0001 130.0017/01/202311 0001 100.00 ---18/01/202342 0002 200.00 12 0002 240.0019/01/202332 0002 180.00 ---20/01/202332 0012 141.07 ---23/01/202372 9993 148.95 ---25/01/202364 0003 920.00 ---26/01/2023--- 22 0052 005.0027/01/202364 0003 920.00 42 0002 040.0030/01/202321 5001 485.00 ---31/01/20231500495.00 ---01/02/202311 000990.00 ---02/02/202321 5001 470.00 ---03/02/202311 000960.00 ---06/02/202331 5001 410.00 ---07/02/202311 000930.00 ---08/02/20231500460.00 ---09/02/202321 000900.00 ---13/02/2023--- 74 0003 600.0014/02/202311 000890.00 ---15/02/202311 000880.00 ---17/02/20231500430.00 110087.0020/02/202315043.00 44 9004 263.0023/02/202315042.50 ---24/02/202321 020846.60 ---27/02/202351 9001 558.00 ---28/02/20231500400.00 42 0001 640.0001/03/202331 9641 571.20 12 0001 620.0002/03/202321 000800.00 ---03/03/2023--- 2504403.2006/03/202311 000790.00 ---07/03/202321 5001 185.00 ---08/03/202341 5001 185.00 --- Buy Side Sell Side Number of executionsNumber of sharesTraded volume in EUR Number of executionsNumber of sharesTraded volume in EURTotal12874 58462 919.32 12874 58462 919.3209/03/202321 000780.00 ---10/03/20232500380.00 ---13/03/20231500375.00 ---15/03/20231500350.00 ---17/03/20231300198.00 ---20/03/20231200128.00 17750.8221/03/2023--- 112381.1829/03/20231300180.00 ---14/04/2023--- 2512 80010 368.0017/04/202351 8001 260.00 ---18/04/2023--- 3600438.0019/04/202394 0002 520.00 ---20/04/202321 300767.00 ---21/04/202331 000580.00 ---25/04/202321 000550.00 ---26/04/2023--- 94 2002 688.0002/05/2023--- 2500325.0004/05/20231300180.00 ---09/05/202311 000580.00 24 0002 400.0010/05/202332 5001 475.00 ---12/05/202311 000590.00 32 0001 200.0015/05/202311 000600.00 ---16/05/202322 0001 160.00 ---17/05/2023--- 42 0001 180.0025/05/202322 0001 160.00 ---29/05/202353 0001 710.00 ---01/06/2023--- 1500290.0006/06/20231300165.00 ---20/06/20231500255.00 ---21/06/20232600300.00 ---
About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal conditions. NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC (a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.
For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverage
Bryan, Garnier & Co Eric Yoo Paris, France
Edison Investment Research Pooya Hemami London, UK
H.C. Wainwright & Co Yi Chen New York, U.S.
Kepler Cheuvreux Arsene Guekam Paris, France The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com Forward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Risks factors which are likely to have a material effect on Nicox’s business are presented in section 2.7 of the ‘Rapport Annuel 2022’ which is available on Nicox’s website (www.nicox.com).Nicox SA
Drakkar 2 - Bât D
2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99
Attachment
EN_KeplerHalfYearlyReportingJune 2023_20230711


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.